Bioprocessing & Pharma
Lundbeck continues neuroscience evolution as CEO keeps company ‘punching above its weight’
By Fraiser Kansteiner · 8/21/2026
Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a “neuroscience challenger” capable of “punching above its weight.”
This is a preview. Read the complete article on Fierce Pharma.
Read the full article →